Follow-up after infants younger than 2 months of age with urinary tract infection in Southern Israel: epidemiologic, microbiologic and disease recurrence characteristics.
The incidence of urinary tract infections (UTI) is 3-4.6% in neonates, 0.7-5.9% in infants up to 1 year of age, 1-3% at the age of 1-5 years and 0.71-2.3% at school age. (1,2) Approximately 7-8% of girls and 2% of boys will develop an UTI during the first 8 years of life. (3) The most common pathogen is Escherichia coli, causing up to 70-90% of all UTIs. (4,5)
Diagnosis of UTI is of major importance, particularly in young ages, because the infection may represent, potentially, the first sign of a congenital defect of the urinary tract. Early diagnosis and treatment are considered to prevent complications such as renal scarring, deteriorating renal function, and hypertension, especially in young infants and children <5 years of age. (6) The most common abnormality diagnosed by imaging investigation is vesico-uretheral reflux (VUR). (6-9) The rate of VUR in children <1 year of age is between 18-35%. (6,8,9) It is known today that severe VUR may be associated with development of renal scars by up to 4-6 times more than a low grade VUR and 8-10 times more likely than in patients without VUR. (6,8,9)
The timing of most UTI recurrences after neonatal UTI is during the first year of life, with peak incidence 2-6 months post infection. (10) In general, UTI recurrence occurs in 30-40% of the children with UTI and around 60% of them will have the recurrence during the first two years of life. In a retrospective study completed between 1978 and 1984 and including 262 children <1 year of age followed for three years after the first episode, 35% boys and 32% girls developed recurrent UTI and the recurrent UTI incidence was higher in children with higher (III-V) degrees of reflux. (11)
Information on the microbiologic characteristics of the recurrent UTI episodes in relation to the microbiology of the initial episodes is limited. The objectives of our study are to describe and characterize the 1st UTI episode in infants <2 months of age admitted at our center during 2005-2009, to determine the incidence of UTI in this population in Southern Israel, to establish the rates of recurrent UTI episodes until the age of 1 year and the microbiologic characteristics of these episodes, and to discuss the appropriate antibiotic treatment policies for the treatment and prophylaxis of UTI in infants.
Patients and methods
This was a retrospective study performed during 2005-2009 and including all the infants <2 months of age admitted to the pediatric departments of the Soroka University Medical Center with the diagnosis of UTI proven by urine culture (obtained by supra-pubic aspiration or bladder catheterization). Our hospital is the only primary and tertiary medical center in Southern Israel and takes care of a population of approximately 1 million patients, out of them around 250,000 children. (3)
Infants <2 months of age, following the hospitalization with UTI, were discharged with the recommendation for antibiotic prophylaxis and for imaging investigations of the urinary tract during the period of two months following the original UTI episode, according to the available recommendations. (6,8) The medical records of the admitted infants, laboratory findings from the bacteriological laboratory and imaging data from the radiology department and the nuclear medicine institute, were searched. Age, sex and ethnicity of the infants with UTI were documented. All urine cultures were obtained (at the initial and also the recurrent UTI episode) by catheterization or suprapubic aspiration. The recovered urine cultures pathogens were considered true uropathogens according to treatment physicians and additional recommendations by the pediatric infectious disease unit of the hospital. Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans were not considered true uropathogens in single pathogen or mixed pathogens-UTI cases without an additional renal anatomic abnormality.
A comparative analysis of the microbiological factors responsible for the first and for the recurrent UTI episodes was performed. The antibiotic coverage and duration of treatment of UTI were documented. The timing of the UTI recurrence was analyzed in relation to the initial UTI episode. Anatomical abnormalities diagnosed during the first episode of UTI were documented as well as all imaging finding completed during the follow-up period. When VUR diagnosis was present, its severity degree was reported.
The antibiotic prophylaxis policy was not well defined at the pediatric department during the study period, leaving at the physicians' decision the specific antibiotic to be administered. However, the local guidelines recommended antibiotic prophylaxis for all infants <2 months of age with first UTI episodes until the completion of imaging studies.
The recommended imaging studies during the study period included the completion of an ultrasound (US) examination during hospitalization or after hospitalization in all cases of infants <2 months of age with UTI and performance of a voiding cystourethrogram (VCUG) after 6-8 weeks following the discharge from the hospital. Additional investigations, like Technetium-Dimercaptosuccinic (DMSA) scan, in specific cases, were performed according to nephrologist's recommendations.
The study was approved by the ethics committee of the hospital.
Data were recorded using the Access Microsoft Office software. Statistical analysis was performed using the SPSS 16.0 software. Contingency table analysis for comparing rates between unmatched samples was performed using the Chi-square or Fisher's exact test, as appropriate. Student's independent samples t-test or ANOVA were used to compare continuous variables.
Overall, 151 infants <2 month of age diagnosed with the 1st UTI episode in life, were enrolled. These infants represented 2.7% of all 5617 infants <2 months of age admitted at the pediatric departments during the study years (22/1129 [1.9%], 34/1205 [2.8%], 45/1302 [3.4%], 24/1217 [2.0%], and 26/1029 [2.5%] during 2005, 2006, 2007, 2008, and 2009, respectively).
The overall incidence of UTI occurring during the first two months of life was 151/73,480 (0.2%) live births during 2005-2009 in the Negev area of Southern Israel, representing an incidence of 2.1 cases/1000 live births. The respective numbers for each year of the study were: 1.5, 2.4, 3.1, 1.6, and 1.7/1000 live births during 2005, 2006, 2007, 2008, and 2009 respectively.
The mean [+ or -] standard deviation age (in days) at UTI diagnosis was 42.26 [+ or -] 31.25 days for the whole study population; no differences were recorded in the mean age at first UTI diagnosis between male and female neonates (38.24 [+ or -] 15.8 vs. 42.26 [+ or -] 31.25, p = 0.06). There were 85 (56.3%) male patients (all circumcised) and 102 (67.5%) patients of Moslem Bedouin ethnicity.
One hundred and twenty (79.5%) young infants with UTI did not suffer from any previous pathologic conditions. The remaining 31 (21.5%) were diagnosed with various anomalies, of them 9 (5.9%) with renal anomalies (6 with hydronephrosis).
Concomitant pathologies were diagnosed at the time of UTI diagnosis in 25 (16.6%) patients with UTI; pneumonia and bronchiolitis were diagnosed concomitantly in 8 (5.3%) cases each and bacterial meningitis in 5 (3.3%).
One pathogen was isolated in 133 (88.1%) UTI episodes. Escherichia coli, Klebsiella spp., Enterococcus spp., Morganella morganii, Proteus spp., and Enterobacter spp. were the most frequently isolated pathogens (53.3%, 10.6%, 5.2%, 5.2%, 4.5%, and 3.9% of all episodes, respectively)--Table 1. Mixed infection caused by two organisms considered as true UTI pathogens was recorded in 18 (11.9%) episodes, with E. coli isolated in 6/18 (33.3%) episodes. In the two patients with mixed UTI with recovery of P. aeruginosa and S. aureus (together with Klebsiella spp. and Enterococcus spp., respectively), both isolates were considered as true uropathogens due to the concomitant presence of renal tract anatomic anomalies (moderate hydronephrosis and VUR degree IV, respectively).
Overall, there were 169 uropathogens, of them 95 (57.9%) E. coli isolates. Klebsiella spp., Enterococcus spp., M. morganii, Proteus spp., and Enterobacter spp. represented the most common UTI pathogens isolated (in decreasing frequency) following E. coli (12.2%, 7.9%, 6.7%, 6.1%, and 5% of all pathogens, respectively).
No statistical differences were recorded between E. coli-UTI cases recorded in male vs. female patients (68.2% vs. 56%, p = 0.5). Significantly more E. coli-UTI cases were recorded in Bedouin patients compared with Jewish patients (70.6% vs. 46.9%, p = 0.005).
Antibiotic prophylaxis following the first UTI episodes
Trimethoprim/sulfamethoxazole (TMP/SMX) was the most common prophylactic antibiotic recommended (68, 45% of all enrolled patients) in the study patients following the first UTI episodes. Amoxicillin and cefuroxime-axetil were the next most common prophylactic antibiotic recommended (20 [13.2%] and 12 [8%] of all enrolled patients). Forty-five (29.8%) of the patients enrolled in the study did not receive any recommendation for antibiotic prophylaxis following the initial UTI episode.
US was performed in 83 (54.9%) patients; 68 (81.9%) of these examinations were reported as normal. The abnormal findings diagnosed in 15 (18.1%) patients included: mild to severe hydronephrosis in all cases, one megaureter and one case suspected of nephrolithiasis. VCUG was performed in 66 (43.7%) and was diagnosed as normal in 52 (78.8%); VUR of degrees IV-V was found in three patients.
Recurrent UTI (Table 2)
Recurrent UTI episodes were recorded in 20/151 (13.2%) patients. One patient developed two UTI recurrences during the first year of life and one patient developed three UTI recurrences within the first year of life. Recurrent UTI was recorded in 13 males and seven female patients; 6/23 (26%) recurrent UTI episode were diagnosed within one month following the discharge after the first UTI episode. Three of the patients with recurrent UTI had a previously diagnosed renal abnormality (all three with hydronephrosis, one of them with uretherovesicular obstruction)
Five of the patients with recurrent UTI did not receive any antibiotic prophylaxis following the first UTI episode. There were 23 uropathogens; no mixed pathogens recurrent UTI episodes were recorded. E. coli was the most frequent UTI pathogen recovered in recurrent UTI (12/23, 52.2% of all recurrent UTI episodes). No differences were recorded in the representation of E. coli among all the pathogens isolated in the first UTI episodes compared with the recurrent UTI episodes (95/151, 62.9% vs. 12/23, 52.2%, p = 0.30).
Seventeen (74%) of the 23 episodes of recurrent UTI were caused by pathogens different (phenotypically) from the pathogen isolated at the first UTI episode. In two of these episodes, the initial and recurrent UTI pathogen was E. coli with a different antibiotic susceptibility profile. Six (26%) of the 23 episodes of recurrent UTI were caused by the same (phenotypically) pathogens as those causing the first UTI episode: four E. coli, one Klebsiella spp. and one Enterobacter spp.
Recurrent UTI episodes occurred in 17/68 (25.0%), 1/12 (8.3%), and 0/20 of patients receiving initial prophylaxis with TMP/SMX, cefuroxime-axetil, or amoxicillin, respectively.
Antibiotic susceptibilities of uropathogens isolated at the initial and recurrent UTI episode (Table 3)
At the initial UTI episode, the antibiotic resistance of E. coli isolates to the most commonly used oral antibiotics was 57.9%, 13.5%, 9.9%, and 5.4% for ampicillin, amoxicillin/clavulanic acid, TMP/SMX, and cefuroxime-axetil. The respective numbers for the two most commonly used IM/IV antibiotic drugs were 3.9% and 2.1% for ceftriaxone and gentamicin. The antibiotic resistance of Klebsiella spp. isolates to the most commonly used oral antibiotics was 90.0%, 21.4%, 14.3%, and 6.3% for ampicillin, amoxicillin/clavulanic acid, cefuroxime-axetil, and TMP/SMX. The respective numbers for the two most commonly used IM/IV antibiotic drugs were 6.3% and 4.8% for ceftriaxone and gentamicin. All 11 M. morganii isolates were resistant to ampicillin. All 13 Enterococcus spp. isolates were susceptible to ampicillin.
The antibiotic resistance of the 12 E. coli isolates recovered in R-UTI patients was 58.3%, 0%, and 0% for ampicillin, TMP/SMX, and cefuroxime-axetil, respectively. Four of the five E. coli isolates examined showed resistance to amoxicillin/clavulanic acid. The respective numbers for the two most commonly used IM/IV antibiotic drugs were 16.6% and 0 for ceftriaxone and gentamicin.
The most recently published information on the diagnosis and management of an initial UTI episode in febrile infants and young children are included in the last (2011) technical report of the subcommittee of UTI of the American Academy of Pediatrics. (7) A meta-analysis was performed on a final amount of 159 relevant publications and revealed a consistent UTI prevalence of 5% among infants and young children 2-24 months of age with fever without obvious source. Evidence was found that delay in the institution of appropriate treatment of pyelonephritis increases the risk of renal damage. A prevalence of VUR of 18-35% among infants/young children with UTI was reported. The report emphasized that normal prenatal US findings may not be sufficient to obviate the need for additional studies if a UTI occurs in infancy and that the accumulated evidence was not supporting antimicrobial prophylaxis to prevent UTI when VUR is found through VCUG. Finally, performance of VCUG after the first UTI for children between 2 and 24 months of age was not recommended anymore. (7) The following (2011) guidelines of the American Academy of Pediatrics did not support the use of antimicrobial prophylaxis to prevent febrile recurrent UTI in infants without grade I-IV VUR. (9) VCUG was not recommended anymore routinely after the first UTI, but is still indicated if renal and bladder ultrasonography reveals hydronephrosis, scaring, or other finding suggestive of either high grade VUR or obstructive uropathy and in other atypical or complex clinical circumstances. The performance of VCUG, however, is recommended in the presence of a recurrence of febrile UTI. (9)
Few data exist in the literature regarding UTIs occurring in infants <2 months of age. The major purpose of our retrospective study was to analyze the epidemiological, microbiological, imaging, and therapeutical aspects of the first episodes of UTI in infants <2 months of age and to follow these infants until the age of one year, in order to track the occurrence of recurrent UTI episodes and to study the appropriateness of current imaging and antibiotic therapeutic guidelines. The major findings of this study were: (1) the UTI incidence was 2.1 cases/1000 live births among infants <2 months of age in Southern Israel; (2) E. coli was responsible for the majority of first and also recurrent UTI episodes; (3) no differences were recorded in the percentages of E. coli among the pathogens isolated at the first and the recurrent UTI episodes; (4) the adherence to diagnostic imaging guidelines for infants <2 months of age with first UTI episodes was partial; (5) recurrent UTI episodes were recorded in relatively few (13.2%) patients and were caused mostly by pathogens phenotypically different than the pathogen isolated at the initial episode; (6) while high rates of resistance to ampicillin were recorded among the E. coli and Klebsiella spp. isolates in the first UTI episode and among E. coli isolates at UTI recurrence, the resistance rate of these pathogens to TMP/SMX and cefuroxime-axetil were low.
We calculated in our study an UTI incidence of 2.1/1000 live births among infants aged 0-2 months living in the Negev area of Southern Israel and a prevalence of 2.7% cases of first UTI episode in life among febrile infants <2 months admitted at the pediatric departments of our hospital during the study years. The prevalence rates are lower than the figures published in the medical literature (reporting a rate of around 5%). (1,4,5,8) The incidence rate reported in our study should be considered reliable, because all our findings are reported in this study as population-based, taking into consideration that the Soroka University Medical Center is the only medical center treating infants and children in the Negev area of southern Israel.
E. coli was responsible for the majority of cases of first UTI. Our data are similar to data previously published in the literature showing a representation of E. coli among first UTI episodes of 60-89%. (8,12,13) The current guidelines for the treatment of neonatal UTI take into consideration these finding but may often be inappropriate for hospitalized infants with non-E. coli UTI, caused in general by pathogens resistant to antibiotics and therefore more difficult to treat. (13) The E. coli isolates recovered from our patients at the first UTI episode, although resistant, in most patients, to ampicillin and also in a considerable number of cases to amoxicillin/clavulanic acid, showed a favorable antibiotic susceptibility profile vs. TMP/SMX, cefuroxime, ceftriaxone, and gentamicin. Furthermore, the resistance rates of Klebsiella spp. to TMP/SMX were also very low. Therefore, and not in accordance with the published literature, TMP/SMX may represent, at least in older children, an acceptable first line empiric antibiotic in the treatment of UTI in young infants.
The R-UTI rates recorded in our study reached 13.2% following an initial UTI episode occurring during the first two months of life. Most prior studies have shown much higher recurrence rate (20-48%) of UTI 6-12 months after an initial UTI episode. (7,9,14) Interestingly, only a few of the patients developing R-UTI episodes in our study had a previously diagnosed renal pathology. The influence of the antibiotic prophylactic treatment administered after the first UTI episode could not be clearly determined in our study. However, 25% of the patients receiving prophylaxis with TMP/SMX developed RUTI episodes (despite low resistance to this antibiotic drug) while no cases of recurrent UTI were diagnosed in patients receiving amoxicillin prophylaxis (despite an unfavorable susceptibility profile of the most frequently isolates pathogens recovered in this study). The effectiveness of long-term prophylactic antibiotic treatment is yet unclear. (6,7,8,9) Williams et al. (15) showed that long-term antibiotic prophylaxis is effective in preventing UTI recurrences, but this effect was not sustained after the interruption of the antibiotic treatment. Shah et al. determined that prophylactic antibiotic is recommended for children <8 years of age with VUR and frequent symptomatic recurrences of UTI ([greater than or equal to] 2 UTI episodes over a 6-month period) and in young children <18 months of age with acute pyelonephritis without any diagnosed reflux using [sup.99m]Tc-DMSA scan. (16) On the other hand, Garin et al. determined that the presence of VUR of mild or moderate degree does not increase the risk for R-UTI, pyelonephritis, or kidney scarring and there is no reason for prophylactic antibiotic. (17) Conway et al. (10) reported rates of 0.007 episodes per person-year of primary UTI up to the age of one year and 0.12 episodes per person-year of recurrent UTI. The authors found that the risk factors for recurrence of UTI included white race, age of 4-5 years, and a VUR of degrees 4-5. Prophylactic antibiotic treatment was not associated with a decrease in the risk of UTI recurrence, but was a risk factor for development of antimicrobial resistance among children with recurrent UTI. (10) In 2014, in a two-year, multisite, randomized, placebo-controlled trial involving 607 children with VUR (80.4% with grade II or III VUR) diagnosed after a first or second febrile or symptomatic urinary tract infection, antimicrobial prophylaxis with TMP/SMX was associated with a substantially reduced risk of recurrence (50%) but not of renal scarring. (18)
We could establish in this study that the overall etiology of the recurrent UTI episodes was similar to that of the initial UTI episode in terms of E. coli and non-E. coli organisms representation and also, importantly, that the majority (64%) of the recurrent UTI episodes were caused by pathogens different than those isolated at the first UTI episode. Our last findings, based on similarity between the antimicrobial profiles of the isolates, were not definitively confirmed by genetic tests demonstrating unequivocally this similarity, and this is one of the limitations of our study.
The imaging guidelines in use at the pediatric division of our hospital during the study period recommended the performance of US examination during hospitalization or shortly after hospitalization in all cases of UTI in young infants, a VCUG examination after 6-8 weeks following the discharge from the hospital. These guidelines were implemented only partially in the enrolled patients.
In conclusion, our study showed that E. coli was responsible for the majority of first UTI in neonates and also in the recurrent UTI episodes of these patients. We could not find any differences in the percentages of E. coli and nonE. coli organisms between the first and the recurrent UTI episodes. Recurrent UTI episodes were recorded in relatively few patients and were caused mostly by pathogens phenotypically different than the pathogen isolated at the initial episode.
Received 27 June 2015
Accepted 11 September 2015
Available online 19 November 2015
Conflicts of interest
The authors declare no conflicts of interest.
(1.) Hoberman A, Chao HP, Keller DM, Hickey R, Davis HW, Ellis D. Prevalence of urinary tract infection in febrile infants. J Pediatr. 1993; 123:17-23.
(2.) Miron D, Shatzberg G, Landau D, Halevy R. Treatment of community-acquired urinary tract infections. Israel J Pediatr. 2001; 38:7-15.
(3.) Israeli Central Bureau of Statistics, Statistical Abstracts of Israel, 2005-2009, Data on Beer-Sheva sub-district population.
(4.) Ismaili K, Lolin K, Damry N, Alexander M, Lepage P, Hall M. Febrile urinary tract infections in 0- to 3-month-old infants: a prospective follow-up study. J Pediatr. 2011; 158:91-4.
(5.) Roberts KB, Charney E, Sweren RJ, Ahonkhai VI, Bergman DA, Coulter MP, et al. Urinary tract infection in infants with unexplained fever: a collaborative study. J Pediatr. 1983; 103:864-7.
(6.) American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on Urinary Tract Infection. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. Pediatrics. 1999; 103:843-52.
(7.) Finnell SME, Carroll AE, Downs. SM and the Subcommittee on Urinary Tract Infection. Technical report- diagnosis and management of an initial UTI in febrile infants and young children. American Academy of Pediatrics. Pediatrics. 2011; 128:e749-70.
(8.) Roberts KB. Urinary tract infection treatment and evaluation. Update. Pediatr Infect Dis J. 2004; 23:1163-4.
(9.) Subcommittee on Urinary Tract Infection. Steering committee on Quality Improvement and Management: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 months. American Academy of Pediatrics. Pediatrics. 2011; 128:595-610.
(10.) Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren. Recurrent urinary tract infections in children. Risk factors and association with prophylactic antimicrobials. JAMA. 2007; 298:179-87.
(11.) Nuutinen M, Uhari M. Recurrence and follow-up after urinary tract infection under the age of 1 year. Pediatr Nephrol. 2001; 16:69-72.
(12.) Ismaili K, Wissing KM, Lolin K, Le PQ, Christophe C, Lepage P, et al. Characteristics of first urinary tract infection with fever in children--a prospective clinical and imaging study. Pediatr Infect Dis J. 2011; 30:371-4.
(13.) Marcus N, Ashkenazi S, Yaari A, Samra Z, Livni G. Non-Escherichia coli versus Escherichia coli community-acquired urinary tract infection in children hospitalized in a tertiary center-relative frequency, risk factors, antimicrobial resistance and outcome. Pediatr Infect Dis J. 2005; 24:581-5.
(14.) Wald ER. Vesicoureteral reflux: the role of antibiotic prophylaxis. Pediatrics. 2006; 117:919-22.
(15.) Williams G, Lee A, Craig J. Antibiotics for the prevention of urinary tract infection in children: a systematic review of randomized controlled trials. J Pediatrics. 2001; 138:868-74.
(16.) Shah G, Upadhyay J. Controversies in the diagnosis and management or urinary tract infections in children. Pediatr Drugs. 2005; 7:339-46.
(17.) Garin E, Olavarria F, Nieto VG, Valenciano B, Campos A, Young L. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics. 2006; 117:626-32.
(18.) The RIVUR Trial Investigators. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014, http://dx.doi.org/10.1056/NEJMoa1401811.
Evgenia Gurevich (a,b), Dov Tchernin (a,c), Ruth Schreyber (a,b), Robert Muller (d), Eugene Leibovitz (c),*
(a) Pediatric Department "A", Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
(b) Pediatric Nephrology Clinics, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
(c) Pediatric Emergency Medicine Department, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
(d) Pediatric Nephrology Department, IVth Pediatric Clinic, University Children Hospital "St. Mary", G.T. Popa University of Medicine and Pharmacy, lasi, Romania
* Corresponding author at: Pediatric Emergency Medicine Department, Soroka University Medical Center, P.O. Box 151, Beer-Sheva 84101, Israel.
E-mail address email@example.com (E. Leibovitz).
Table 1--Pathogen distribution: 151 episodes of first UTI occurring in 151 neonates <2 months of age. Pathogens n (%) (1) Pathogen 133 (88.1) Escherichia coli 85 (56.3) Klebsiella spp. 16 (10.6) Enterococcus spp. 8 (5.2) Morganella morganii 8 (5.2) Proteus spp. 7 (4.5) Enterobacter spp. 6 (3.9) Citrobacter spp. 2 (1.3) Serratia marcescens 1 (0.6) (2) Pathogens (mixed infection) 18 (11.9) Escherichia coli + Enterococcus spp. 3 (1.9) Escherichia coli + Klebsiella spp. 2 (1.3) Escherichia coli + Proteus spp. 2 (1.3) Escherichia coli + type b Haemophilus influenzae 1 (0.6) Escherichia coli + Morganella morganii 1 (0.6) Escherichia coli + Acinetobacter spp. 1 (0.6) Klebsiella spp. + Enterococcus spp. 1 (0.6) Klebsiella spp. + Pseudomonas spp. 1 (0.6) Morganella morganii + Enterococcus spp. 1 (0.6) Morganella morganii + Klebsiella spp. 1 (0.6) Enterobacter spp. + Enterococcus spp. 1 (0.6) Enterobacter spp. + Proteus spp. 1 (0.6) Proteus spp. + Enterococcus spp. 1 (0.6) Enterococcus spp. + Staphylococcus aureus 1 (0.6) Table 2--Epidemiologic, microbiologic, and therapeutic characteristics: 20 patients (23 episodes) with UTI recurrence. No. M/F Age at Renal background Pathogen in 1st recurrence pathology episode (months) 1 F 12 E. coli 2 M 1 Proteus spp. 3 F 2 Proteus spp. 4 F 3 E. coli 5 M 2 Enterobacter spp. + Enterococcus spp. 6 F 2 E. coli 7 M 2 E. coli 8 M 3 E. coli 9 F 3 E. coli 10 M 6 E. coli 11 F 4 M. morganii 12 M 7 E. coli 13 M 6 E. coli 14 F 11 Proteus spp. 15 M 11 Hydronephrosis Enterobacter spp. 16 M 10 Hydronephrosis Enterobacter spp. 17 M 4 E. coli 18.1 M 7 Klebsiella spp. 18.2 9 Klebsiella spp. 19.1 3 Congenital Klebsiella spp. 19.2 M 7 megaurether, UVJ Klebsiella spp. 19.3 10 obstruction, Klebsiella spp. 20 M 12 hydronephrosis Klebsiella spp. No. Pathogen in 2nd Antimicrobial episode prophylaxis after first UTI 1 E. coli TMP/SMX 2 C. albicans TMP/SMX 3 P. aeruginosa TMP/SMX 4 Citrobacter spp. TMP/SMX 5 E. coli TMP/SMX 6 Enterobacter spp. NA 7 Klebsiella spp. NA 8 E. coli TMP/SMX 9 E. coli Cefuroxime-axetil 10 E. coli TMP/SMX 11 E. coli TMP/SMX 12 E. coli TMP/SMX 13 E. coli TMP/SMX 14 E. coli NA 15 Enterococcus spp. TMP/SMX 16 Enterobacter spp. TMP/SMX 17 E. coli NA 18.1 Proteus spp. TMP/SMX 18.2 E. coli TMP/SMX 19.1 S. aureus TMP/SMX 19.2 C. albicans TMP/SMX 19.3 E. coli TMP/SMX 20 Klebsiella spp. NA TMP-SMX, trimethoprim-sulfamethoxazole; NA, not administered; UVJ, urethero-vesicular junction. Table 3--Antibiotic non-susceptibilities * of the most frequently uropathogens isolated at the initial and the recurrent UTI episodes Antibiotic Organism E. coli n (%) Klebsiella spp. n (%) UTI episode timing I ** II ** I II n = 95 n = 12 n = 21 n = 2 Ampicillin 55/95 (57.9) 7/12 (58.3) 18/20 (90) 2/2 (100) TMP/SMX 7/71 (9.9) 0/10 1/16 (6.3) 0/2 Cefuroxime 5/92 (5.4) 0/10 3/21 (14.3) 1/2 (50) Ceftriaxone 3/77 (3.9) 2/12 (100) 1/16 (6.3) 0/1 Gentamicin 2/94 (2.1) 0/12 1/21 (4.8) -- Amoxicillin/ 5/37 (13.5) 4/5 (80) 3/14 (21.4) -- clavulanic acid Ciprofloxacin 3/29 (10.3) 0/1 2/5 (40) -- Antibiotic Organism M. morganii n (%) Proteus spp. n (%) UTI episode timing I II I II n = 11 n = 0 n = 11 n = 1 Ampicillin 11/11 (100) 7/11 (63.6) 2/2 (100) TMP/SMX 2/8 (25) 0/5 1/1 (100) Cefuroxime 1/10 (10) 0/11 0/1 Ceftriaxone 2/9 (22.2) 1/11 (9.1) -- Gentamicin 3/11 (27.3) 0/11 0/1 Amoxicillin/ 1/4 (25) 4/9 (44.4) -- clavulanic acid Ciprofloxacin 1/3 (33.3) 2/5 (40) -- Antibiotic Organism Enterobacter spp. n (%) Enterococcus spp. n (%) UTI episode timing I II I II n = 8 n = 2 n = 14 n = 1 Ampicillin 7/8 (87.5) 2/2 (100) 0/13 1/1 (100) TMP/SMX 0/6 -- 2/10 (20) -- Cefuroxime 1/7 (14.3) 2/2 (100) 3/10 (30) -- Ceftriaxone 0/7 2/2 (100) 3/8 (37.5) -- Gentamicin 0/8 0/2 2/13 (15.4) 0/1 Amoxicillin/ 1/1 (100) 1/1 (100) 3/7 (42.9) -- clavulanic acid Ciprofloxacin 0/1 -- 6/7 (85.7) -- * Antibiotic susceptibilities for some antibiotic drugs not determined for all pathogens. ** I, initial UTI episode; II, recurrent UTI episode. TMP/SMX, trimethoprim/sulfamethoxazole.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Gurevich, Evgenia; Tchernin, Dov; Schreyber, Ruth; Muller, Robert; Leibovitz, Eugene|
|Publication:||The Brazilian Journal of Infectious Diseases|
|Date:||Jan 1, 2016|
|Previous Article:||Nephrotoxicity during tenofovir treatment: a three-year follow-up study in a Brazilian reference clinic.|
|Next Article:||Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease.|